Teclistamab in Patients With Relapsed or Refractory Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Teclistamab, a B-Cell Maturation Antigen × CD3 Bispecific Antibody, in Patients With Relapsed or Refractory Multiple Myeloma (MajesTEC-1): A Multicentre, Open-Label, Single-Arm, Phase 1 Study
Lancet 2021 Aug 10;[EPub Ahead of Print], SZ Usmani, AL Garfall, NWCJ van de Donk, H Nahi, JF San-Miguel, A Oriol, L Rosinol, A Chari, M Bhutani, L Karlin, L Benboubker, L Pei, R Verona, S Girgis, T Stephenson, Y Elsayed, J Infante, JD Goldberg, A Banerjee, MV Mateos, A KrishnanFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.